Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Using informative features in machine learning based method for COVID-19 drug repurposing
Inst Res Fundamental Sci IPM, Sch Biol Sci, Tehran, Iran..ORCID-id: 0000-0001-9045-9592
Islamic Azad Univ, Dept Math, Qazvin Branch, Qazvin, Iran..
KTH, Skolan för elektroteknik och datavetenskap (EECS), Datavetenskap, Beräkningsvetenskap och beräkningsteknik (CST). KTH, Centra, Science for Life Laboratory, SciLifeLab.
2021 (engelsk)Inngår i: Journal of Cheminformatics, E-ISSN 1758-2946, Vol. 13, nr 1, artikkel-id 70Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Coronavirus disease 2019 (COVID-19) is caused by a novel virus named Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). This virus induced a large number of deaths and millions of confirmed cases worldwide, creating a serious danger to public health. However, there are no specific therapies or drugs available for COVID-19 treatment. While new drug discovery is a long process, repurposing available drugs for COVID-19 can help recognize treatments with known clinical profiles. Computational drug repurposing methods can reduce the cost, time, and risk of drug toxicity. In this work, we build a graph as a COVID-19 related biological network. This network is related to virus targets or their associated biological processes. We select essential proteins in the constructed biological network that lead to a major disruption in the network. Our method from these essential proteins chooses 93 proteins related to COVID-19 pathology. Then, we propose multiple informative features based on drug-target and protein-protein interaction information. Through these informative features, we find five appropriate clusters of drugs that contain some candidates as potential COVID-19 treatments. To evaluate our results, we provide statistical and clinical evidence for our candidate drugs. From our proposed candidate drugs, 80% of them were studied in other studies and clinical trials.

sted, utgiver, år, opplag, sider
Springer Nature , 2021. Vol. 13, nr 1, artikkel-id 70
Emneord [en]
Coronavirus disease 2019, SARS-CoV-2, Protein-protein interaction, Clustering method
HSV kategori
Identifikatorer
URN: urn:nbn:se:kth:diva-303049DOI: 10.1186/s13321-021-00553-9ISI: 000698428500001PubMedID: 34544500Scopus ID: 2-s2.0-85115141169OAI: oai:DiVA.org:kth-303049DiVA, id: diva2:1600920
Merknad

QC 20211006

Tilgjengelig fra: 2021-10-06 Laget: 2021-10-06 Sist oppdatert: 2022-06-25bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Taheri, Golnaz

Søk i DiVA

Av forfatter/redaktør
Aghdam, RosaTaheri, Golnaz
Av organisasjonen
I samme tidsskrift
Journal of Cheminformatics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 343 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf